UPDATED Thursday, Feb. 17, 2022, 4:00 p.m. EDT—The U.S. Health Resources and Services Administration (HRSA) said this afternoon, “The 340B program is an essential component of the safety net system that helps make health care and prescription drugs more affordable for millions of Americans. HRSA respectfully disagrees with the recent District Court opinion, and we will continue to work to ensure the program delivers for underserved patient populations and frontline health care providers.”
Yesterday’s court decision in AstraZeneca’s 340B contract pharmacy lawsuit made the score 6-0 in favor of drug manufacturers in their fight with the federal government over the legality of its May 17, 2021, letters telling Astra, Lilly, Novartis, Novo Nordisk, Sanofi, and United Therapeutics that their actions have resulted in overcharges and are in direct violation of the 340B statute.
Yesterday’s court decision in AstraZeneca’s 340B contract pharmacy lawsuit made the final score 6-0 in favor of drug manufacturers in their fight with the federal government over the legality of its May 17, 2021, letters telling Astra, Lilly, Novartis, Novo Nordisk, Sanofi, and United Therapeutics that their actions have resulted in overcharges and are in direct violation of the 340B statute.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
